199 related articles for article (PubMed ID: 33998886)
21. Clinical features associated with ADB-BUTINACA exposure in patients attending emergency departments in England.
King A; Hill SL; Pucci M; Bailey G; Keating L; Macfarlane R; Cantle F; Hudson S; Thomas SHL
Clin Toxicol (Phila); 2022 Oct; 60(10):1094-1098. PubMed ID: 35943421
[TBL] [Abstract][Full Text] [Related]
22. Cannabimimetic effects of abused indazole-carboxamide synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA and 5F-ADB-PINACA in mice: Tolerance, dependence and withdrawal.
Wilson CD; Hiranita T; Fantegrossi WE
Drug Alcohol Depend; 2022 Jul; 236():109468. PubMed ID: 35643039
[TBL] [Abstract][Full Text] [Related]
23. Adding more "spice" to the pot: A review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists.
Alam RM; Keating JJ
Drug Test Anal; 2020 Mar; 12(3):297-315. PubMed ID: 31854124
[TBL] [Abstract][Full Text] [Related]
24. "Spice"-related deaths in and around Munich, Germany: A retrospective look at the role of synthetic cannabinoid receptor agonists in our post-mortem cases over a seven-year period (2014-2020).
Groth O; Roider G; Angerer V; Schäper J; Graw M; Musshoff F; Auwärter V
Int J Legal Med; 2023 Jul; 137(4):1059-1069. PubMed ID: 37072496
[TBL] [Abstract][Full Text] [Related]
25. Spicing it up - synthetic cannabinoid receptor agonists and psychosis - a systematic review.
Hobbs M; Kalk NJ; Morrison PD; Stone JM
Eur Neuropsychopharmacol; 2018 Dec; 28(12):1289-1304. PubMed ID: 30454908
[TBL] [Abstract][Full Text] [Related]
26. [Intoxications with synthetic cannabinoids].
Zanen JG; Leegwater E; Schippers EF; Wilms EB
Ned Tijdschr Geneeskd; 2023 Mar; 167():. PubMed ID: 36943159
[TBL] [Abstract][Full Text] [Related]
27. [Intoxications with synthetic cannabinoids].
Zanen JG; Leegwater E; Schippers EF; Wilms EB
Ned Tijdschr Geneeskd; 2023 Feb; 166():. PubMed ID: 36752668
[TBL] [Abstract][Full Text] [Related]
28. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M
Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
[TBL] [Abstract][Full Text] [Related]
29. Synthetic cannabis: adverse events reported to the New Zealand Pharmacovigilance Centre.
Robson H; Braund R; Glass M; Ashton J; Tatley M
Clin Toxicol (Phila); 2021 Jun; 59(6):472-479. PubMed ID: 33156704
[TBL] [Abstract][Full Text] [Related]
30. The impact of legislation on acute synthetic cannabinoid harms resulting in ambulance attendance.
Grigg J; Killian JJ; Matthews S; Scott D; Arunogiri S; Manning V; Taylor DA; Crossin R; Smith K; Lubman DI
Int J Drug Policy; 2020 Apr; 79():102720. PubMed ID: 32279004
[TBL] [Abstract][Full Text] [Related]
31. New psychoactive substance use as a survival strategy in rural marginalised communities in Hungary.
Csák R; Szécsi J; Kassai S; Márványkövi F; Rácz J
Int J Drug Policy; 2020 Nov; 85():102639. PubMed ID: 31911024
[TBL] [Abstract][Full Text] [Related]
32. Increases in synthetic cannabinoids-related harms: Results from a longitudinal web-based content analysis.
Lamy FR; Daniulaityte R; Nahhas RW; Barratt MJ; Smith AG; Sheth A; Martins SS; Boyer EW; Carlson RG
Int J Drug Policy; 2017 Jun; 44():121-129. PubMed ID: 28578250
[TBL] [Abstract][Full Text] [Related]
33. Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011-2014.
Palamar JJ; Su MK; Hoffman RS
Am J Drug Alcohol Abuse; 2016; 42(1):39-47. PubMed ID: 26678258
[TBL] [Abstract][Full Text] [Related]
34. Narrative Review of the Pharmacodynamics, Pharmacokinetics, and Toxicities of Illicit Synthetic Cannabinoid Receptor Agonists.
Lea Houston M; Morgan J; Kelso C
Mini Rev Med Chem; 2024; 24(1):92-109. PubMed ID: 37190813
[TBL] [Abstract][Full Text] [Related]
35. From Bumps to Binges: Overview of Deaths Associated with Cocaine in England, Wales and Northern Ireland (2000-2019).
Rooney B; Sobiecka P; Rock K; Copeland C
J Anal Toxicol; 2023 Mar; 47(3):207-215. PubMed ID: 36611264
[TBL] [Abstract][Full Text] [Related]
36. Recent Use of Synthetic Cannabinoids, Synthetic Opioids, and Other Psychoactive Drug Groups among High-risk Drug Users.
Shapira B; Berkovitz R; Rosca P; Neumark Y
J Psychoactive Drugs; 2020; 52(4):334-343. PubMed ID: 32345134
[TBL] [Abstract][Full Text] [Related]
37. Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study.
Hill SL; Najafi J; Dunn M; Acheampong P; Kamour A; Grundlingh J; Blain PG; Thomas SH
Clin Toxicol (Phila); 2016 Sep; 54(8):638-43. PubMed ID: 27251903
[TBL] [Abstract][Full Text] [Related]
38. Large-scale evaluation of ion mobility spectrometry for the rapid detection of synthetic cannabinoid receptor agonists in infused papers in prisons.
Norman C; McKirdy B; Walker G; Dugard P; NicDaéid N; McKenzie C
Drug Test Anal; 2021 Mar; 13(3):644-663. PubMed ID: 33058556
[TBL] [Abstract][Full Text] [Related]
39. Synthetic cannabinoid receptor agonists are monoamine oxidase-A selective inhibitors.
Hindson SA; Andrews RC; Danson MJ; van der Kamp MW; Manley AE; Sutcliffe OB; Haines TSF; Freeman TP; Scott J; Husbands SM; Blagbrough IS; Anderson JLR; Carbery DR; Pudney CR
FEBS J; 2023 Jun; 290(12):3243-3257. PubMed ID: 36708234
[TBL] [Abstract][Full Text] [Related]
40. [Synthetic Cannabinoid Receptor Agonist-Associated Psychotic Disorder: A Case Report].
Sönmez İ; Köşger F
Turk Psikiyatri Derg; 2016; 27(1):63-6. PubMed ID: 27369687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
